Hlb Pharmaceutical Co Stock Probability Of Bankruptcy
| 047920 Stock | KRW 22,000 550.00 2.56% |
HLB |
HLB Pharmaceutical Co Company chance of distress Analysis
HLB Pharmaceutical's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current HLB Pharmaceutical Probability Of Bankruptcy | Less than 19% |
Most of HLB Pharmaceutical's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HLB Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of HLB Pharmaceutical probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting HLB Pharmaceutical odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of HLB Pharmaceutical Co financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, HLB Pharmaceutical Co has a Probability Of Bankruptcy of 19.0%. This is 56.11% lower than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The probability of bankruptcy for all Republic of Korea stocks is 52.3% higher than that of the company.
HLB Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HLB Pharmaceutical's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HLB Pharmaceutical could also be used in its relative valuation, which is a method of valuing HLB Pharmaceutical by comparing valuation metrics of similar companies.HLB Pharmaceutical is currently under evaluation in probability of bankruptcy category among its peers.
HLB Fundamentals
| Return On Equity | -11.39 | |||
| Return On Asset | 0.0219 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 216.14 B | |||
| Shares Outstanding | 13.85 M | |||
| Shares Owned By Insiders | 25.75 % | |||
| Shares Owned By Institutions | 0.13 % | |||
| Price To Sales | 5.60 X | |||
| Revenue | 62.85 B | |||
| Gross Profit | 18.04 B | |||
| EBITDA | 3.08 B | |||
| Net Income | (13.23 B) | |||
| Cash And Equivalents | 6.64 B | |||
| Total Debt | 2.14 B | |||
| Debt To Equity | 0.74 % | |||
| Current Ratio | 1.26 X | |||
| Cash Flow From Operations | (1.32 B) | |||
| Number Of Employees | 14 | |||
| Beta | 1.83 | |||
| Market Capitalization | 173.79 B | |||
| Total Asset | 127.63 B | |||
| Z Score | 48.6 | |||
| Net Asset | 127.63 B |
About HLB Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HLB Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HLB Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HLB Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with HLB Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLB Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLB Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against HLB Stock
The ability to find closely correlated positions to HLB Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLB Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLB Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLB Pharmaceutical Co to buy it.
The correlation of HLB Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLB Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLB Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLB Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLB Stock
HLB Pharmaceutical financial ratios help investors to determine whether HLB Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLB with respect to the benefits of owning HLB Pharmaceutical security.